ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Retrotope Announces First Dosing of RT001 in Friedreich’s Ataxia Study americanpharmaceuticalreview
January 15, 2020Retrotope has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the inherited ataxias. RT001, a stabilized fatty acid drug, has been shown to reduce lipid peroxidation leading to cell death in ...
Pharma Sources Insight January 2025
